Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

In a settlement on September 1, the U.S. Federal Trade Commission cleared Amgen to proceed with its $27.8 billion acquisition of Horizon Therapeutics after several months of scrutiny. Some experts say the agreement is a setback for the agency.